For the third study in the Kinect series, we were again charged with recruiting patients who suffer from tardive dyskinesia (TD), a condition characterized by involuntary facial and body movements in people who have schizophrenia or schizoaffective disorder, bipolar disorder, or mood disorder. Like the first two studies, the Kinect 3 Study was testing a treatment option to help reduce the severity of TD symptoms. Maintaining our core message, we targeted patients and caregivers in a respectful way to encourage participation.
Our Facebook and online advertising campaigns generated 9 million impressions to our target audience and provided more than 36,000 visitors to the study website. As part of our educational outreach initiative, we partnered with the National Alliance on Mental Illness (NAMI) to provide important information on TD to mental health care workers in site communities. These mental health care workers then became referral sources for the study.
At a Glance